BioStock: Annexin receives FDA approval for phase II study

Earlier this week, Annexin Pharmaceuticals announced that they had received green light from FDA to begin a phase II clinical trial within RVO – a step that the company describes as the most important in its history. The FDA’s decision, which provides a quality seal for the company’s project, also means a shorter path to the application for phase II within additional indications.

Read the full article about Annexin Pharmaceuticals at biostock.se:

https://www.biostock.se/en/2022/04/annexin-receives-fda-approval-for-phase-ii-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/